Skip to main content
Skip to main content
ATR logo

AptarGroup, Inc. (ATR)

For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

AptarGroup, Inc. (ATR) trades at $121.06 with AI Score 54/100 (Hold). AptarGroup, Inc. develops and manufactures dispensing, sealing, and material science solutions for various industries. Market cap: 8B, Sector: Healthcare.

Last analyzed: Feb 8, 2026
AptarGroup, Inc. develops and manufactures dispensing, sealing, and material science solutions for various industries. The company operates through three segments: Pharma, Beauty + Home, and Food + Beverage.
54/100 AI Score Target $161.43 (+33.3%) MCap 8B Vol 2M

AptarGroup, Inc. (ATR) Healthcare & Pipeline Overview

CEOStephan Tanda
Employees13000
HeadquartersCrystal Lake, IL, US
IPO Year1993

AptarGroup delivers innovative dispensing and sealing solutions across diverse markets, offering a stable investment with consistent profitability and a commitment to sustainable solutions, driven by its robust Pharma segment and strategic partnerships, positioning it for continued growth and shareholder value.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Feb 8, 2026

Investment Thesis

AptarGroup presents a notable research candidate due to its diversified business model, strong presence in the healthcare sector, and commitment to innovation. With a current P/E ratio of 22.23 and a profit margin of 10.4%, the company demonstrates consistent profitability. The dividend yield of 1.38% provides a steady income stream for investors. Growth will be fueled by expanding its Pharma segment, capitalizing on strategic partnerships, and increasing demand for sustainable packaging solutions. The company's beta of 0.48 suggests lower volatility compared to the broader market, making it a noteworthy option for risk-averse investors. AptarGroup's focus on innovation and strategic collaborations are expected to drive long-term value creation and shareholder returns.

Based on FMP financials and quantitative analysis

Key Highlights

  • Market capitalization of $8.85 billion, reflecting substantial investor confidence.
  • P/E ratio of 22.23, indicating a reasonable valuation relative to earnings.
  • Profit margin of 10.4%, demonstrating solid profitability and operational efficiency.
  • Gross margin of 24.4%, showcasing the company's ability to manage production costs effectively.
  • Dividend yield of 1.38%, providing a consistent income stream for shareholders.

Competitors & Peers

Strengths

  • Diversified product portfolio across multiple sectors.
  • Strong presence in the high-margin pharmaceutical market.
  • Global distribution network.
  • Commitment to innovation and sustainability.

Weaknesses

  • Dependence on key suppliers for raw materials.
  • Exposure to currency fluctuations.
  • Potential impact from regulatory changes in the healthcare sector.
  • Competition from larger, more diversified companies.

Catalysts

  • Expansion of the Pharma segment through new product launches and strategic partnerships.
  • Increasing demand for sustainable packaging solutions driving growth in the Beauty + Home and Food + Beverage segments.
  • Potential acquisitions to expand product offerings and market reach.
  • Continued innovation in digital therapies and services.
  • Geographic expansion in emerging markets.

Risks

  • Economic downturns affecting consumer spending on beauty and personal care products.
  • Changes in healthcare regulations and reimbursement policies impacting the Pharma segment.
  • Intense competition from established players in the dispensing and sealing solutions market.
  • Disruptions in the supply chain affecting the availability of raw materials.
  • Currency fluctuations impacting profitability.

Growth Opportunities

  • Expansion in the Pharma Segment: The increasing demand for advanced drug delivery systems, particularly in respiratory and injectable medications, presents a significant growth opportunity for AptarGroup's Pharma segment. This segment can leverage its existing product portfolio and strategic collaborations to capture a larger market share. The global drug delivery market is projected to reach $25 billion by 2028, offering substantial growth potential for AptarGroup.
  • Strategic Partnerships and Collaborations: AptarGroup's strategic partnership with PureCycle Technologies LLC to develop ultra-pure recycled polypropylene for dispensing applications aligns with the growing demand for sustainable packaging solutions. This collaboration not only enhances the company's environmental credentials but also opens up new market opportunities. The market for sustainable packaging is expected to reach $450 billion by 2027, providing a significant growth avenue for AptarGroup.
  • Geographic Expansion in Emerging Markets: Expanding its presence in emerging markets, particularly in Asia and Latin America, offers significant growth opportunities for AptarGroup. These regions are experiencing rapid economic growth and increasing demand for healthcare and consumer products, creating a favorable environment for AptarGroup's products and services. The emerging markets are expected to contribute significantly to the global growth of the dispensing and sealing solutions market.
  • Innovation in Digital Therapies and Services: AptarGroup's collaboration with Sonmol to develop a digital therapies and services platform targeting respiratory and other diseases positions the company at the forefront of digital healthcare innovation. This initiative allows AptarGroup to offer value-added services to its customers and differentiate itself from competitors. The digital health market is projected to reach $660 billion by 2025, presenting a substantial growth opportunity for AptarGroup.
  • Penetration of the Food and Beverage Market: The Food + Beverage segment offers opportunities to expand its product offerings and market reach. By introducing innovative dispensing and non-dispensing closures, elastomeric flow control components, spray pumps, and aerosol valves, AptarGroup can cater to the evolving needs of the food and beverage industry. The global food and beverage packaging market is expected to reach $400 billion by 2026, providing a significant growth opportunity for AptarGroup.

Opportunities

  • Expansion into emerging markets with growing healthcare needs.
  • Increased demand for sustainable packaging solutions.
  • Strategic acquisitions to expand product offerings.
  • Development of new drug delivery technologies.

Threats

  • Intense competition from established players.
  • Economic downturns affecting consumer spending.
  • Changes in healthcare regulations and reimbursement policies.
  • Disruptions in the supply chain.

Competitive Advantages

  • Diversified product portfolio across multiple industries.
  • Strong presence in the regulated pharmaceutical market.
  • Global reach with operations in Asia, Europe, Latin America, and North America.
  • Strategic partnerships and collaborations for innovation.

About ATR

AptarGroup, Inc., founded in 1992 and headquartered in Crystal Lake, Illinois, is a global leader in providing a wide array of dispensing, sealing, and material science solutions. The company operates through three primary segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma segment is a significant driver of AptarGroup's revenue, offering pumps for nasal allergy treatments, metered dose inhaler valves for respiratory ailments, elastomer components for injectable primary packaging, and active material science solutions. The Beauty + Home segment provides pumps, closures, aerosol valves, accessories, and sealing solutions for the personal care and home care markets, as well as pumps and decorative components for the beauty market. The Food + Beverage segment offers dispensing and non-dispensing closures, elastomeric flow control components, spray pumps, and aerosol valves. AptarGroup serves a global clientele through its direct sales force, independent representatives, and distributors across Asia, Europe, Latin America, and North America. The company's commitment to innovation is underscored by its strategic partnership with PureCycle Technologies LLC to develop ultra-pure recycled polypropylene for dispensing applications, and its collaboration with Sonmol to create a digital therapies and services platform targeting respiratory and other diseases. This diversified approach and focus on innovation positions AptarGroup as a key player in its industry.

What They Do

  • Develop and manufacture dispensing solutions for the pharmaceutical industry.
  • Provide sealing solutions for various applications.
  • Create material science solutions for different markets.
  • Offer pumps and closures for the beauty and personal care markets.
  • Supply dispensing and non-dispensing closures for the food and beverage industry.
  • Provide elastomer components for injectable primary packaging.
  • Develop active material science solutions.

Business Model

  • Manufactures and sells dispensing, sealing, and material science solutions.
  • Operates through three segments: Pharma, Beauty + Home, and Food + Beverage.
  • Generates revenue through direct sales, independent representatives, and distributors.
  • Focuses on innovation and strategic partnerships to drive growth.

Industry Context

AptarGroup operates in the medical instruments and supplies industry, which is experiencing steady growth driven by increasing healthcare expenditure and demand for advanced drug delivery systems. The market is competitive, with players like AVTR, GMED, GRFS, HALO, and HSIC vying for market share. AptarGroup differentiates itself through its diversified product portfolio, global reach, and focus on innovative and sustainable solutions. The company's strong presence in the Pharma segment positions it well to capitalize on the growing demand for advanced drug delivery systems and injectable primary packaging components.

Key Customers

  • Pharmaceutical companies requiring drug delivery systems.
  • Beauty and personal care companies needing pumps and closures.
  • Food and beverage companies requiring dispensing solutions.
  • Healthcare providers using injectable primary packaging.
AI Confidence: 73% Updated: Feb 8, 2026

Financials

Chart & Info

AptarGroup, Inc. (ATR) stock price: $121.06 (-2.91, -2.35%)

Latest News

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ATR.

Price Targets

Consensus target: $161.43

MoonshotScore

54/100

What does this score mean?

The MoonshotScore rates ATR's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

What Investors Ask About AptarGroup, Inc. (ATR) — Healthcare

What does AptarGroup, Inc. do?

AptarGroup, Inc. is a global provider of dispensing, sealing, and material science solutions for a variety of industries, including pharmaceutical, beauty, personal care, home care, food, and beverage. The company operates through three segments: Pharma, Beauty + Home, and Food + Beverage. It offers a range of products, including pumps for nasal allergy treatments, metered dose inhaler valves, closures, aerosol valves, and elastomeric flow control components. AptarGroup's solutions are used by a diverse customer base worldwide, contributing to its position as a key player in the dispensing and packaging industry.

Is ATR stock worth researching?

ATR stock presents a balanced investment opportunity. The company's diversified business model, strong presence in the healthcare sector, and commitment to innovation are positive factors. With a P/E ratio of 22.23 and a dividend yield of 1.38%, the stock offers a combination of growth potential and income. However, investors may want to evaluate the competitive landscape and potential risks, such as economic downturns and regulatory changes. Overall, ATR stock may be a suitable investment for those seeking stable growth and income in the healthcare sector.

What are the main risks for ATR?

AptarGroup faces several risks, including intense competition from established players, economic downturns affecting consumer spending, changes in healthcare regulations and reimbursement policies, disruptions in the supply chain, and currency fluctuations. The company's dependence on key suppliers for raw materials and exposure to currency fluctuations could impact profitability. Additionally, changes in healthcare regulations could affect the demand for its pharmaceutical products. Investors should carefully consider these risks before investing in ATR stock.

What are the key factors to evaluate for ATR?

AptarGroup, Inc. (ATR) currently holds an AI score of 54/100, indicating moderate score. The stock trades at a P/E of 21.4x, near the S&P 500 average (~20-25x). Analysts target $161.43 (+33% from $121.06). Key strength: Diversified product portfolio across multiple sectors. Primary risk to monitor: Economic downturns affecting consumer spending on beauty and personal care products. This is not financial advice.

How frequently does ATR data refresh on this page?

ATR prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven ATR's recent stock price performance?

Recent price movement in AptarGroup, Inc. (ATR) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $161.43 implies 33% upside from here. Notable catalyst: Diversified product portfolio across multiple sectors. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider ATR overvalued or undervalued right now?

Determining whether AptarGroup, Inc. (ATR) is overvalued or undervalued requires examining multiple metrics. Its P/E ratio is 21.4. Analysts target $161.43 (+33% from current price), suggesting analysts see upside potential. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying ATR?

Before investing in AptarGroup, Inc. (ATR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .

Data provided for informational purposes only.

Analysis Notes
  • Information is based on available data and may be subject to change.
Data Sources

Popular Stocks